PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Analyze analyst forecasts for the company and compare them with competitors.
1.01M
Worse than ADAP's estimated revenue of 27.41M.
-202.40K
Better than ADAP's estimated ebitda of -168.80M.
-1.35
Worse than ADAP's estimated eps of -1.09.
-35.97M
Better than ADAP's estimated net income of -176.17M.
-202.40K
Better than ADAP's estimated ebit of -104.79M.
37.50M
Better than ADAP's estimated sg&a expense of 345.83M.
Analyze DCF forecasts for the company and compare them with competitors.
No Data
No DCF data available for this metric in the selected year.
-50.53%
Worse than ADAP's revenue growth rate of 88.84%.
No Data
No DCF data available for this metric in the selected year.
-20.00%
Better than ADAP's ebitda margin of -85.92%.
No Data
No DCF data available for this metric in the selected year.
-20.00%
Better than ADAP's ebit margin of -87.18%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
100.00%
Better than ADAP's cash as percentage of revenue of 97.03%.
No Data
No DCF data available for this metric in the selected year.
40.00%
Worse than ADAP's receivables as percentage of revenue of 25.99%.
No Data
No DCF data available for this metric in the selected year.
40.00%
Worse than ADAP's inventories as percentage of revenue of 14.73%.
No Data
No DCF data available for this metric in the selected year.
100.00%
Worse than ADAP's payables as percentage of revenue of 47.17%.
No Data
No DCF data available for this metric in the selected year.
-29.43%
Worse than ADAP's capex as percentage of revenue of -56.61%.
4.99%
Better than ADAP's weighted average cost of capital (wacc) of 6.28%.
5.02%
Better than ADAP's cost of equity of 17.51%.
4.08%
Better than ADAP's cost of debt of 4.51%.
-0.23
Better than ADAP's beta of 2.85.
30.07M
Better than ADAP's diluted shares outstanding of 42.05M.
1.57M
Better than ADAP's total debt of 74.21M.
49.31M
Better than ADAP's total equity of 11.69M.
50.89M
Worse than ADAP's total capital of 85.89M.
3.09%
Better than ADAP's debt weighting of 86.40%.
96.91%
Better than ADAP's equity weighting of 13.60%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
2.00%
Equal to ADAP's long-term growth rate of 2.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-71.33M
Better than ADAP's net debt of -16.93M.
71.33M
Better than ADAP's equity value of -75.14B.
2.37
Better than ADAP's equity value per share of -1786.98.
View analysts' price targets and recommendations, and compare them with competitors.
$11.07
Analysts expect the stock price to increase by 521.91%.
Buy
Positive consensus among analysts.